[EN] AZAINDOLES AS JANUS KINASE INHIBITORS<br/>[FR] AZAINDOLES COMME INHIBITEURS DE JANUS KINASE
申请人:MERCK SHARP & DOHME
公开号:WO2011137022A1
公开(公告)日:2011-11-03
The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof. Compounds of formula I are inhibitors of Janus kinases and as such are useful for the treatment of various diseases and conditions mediated by said enzymes, such as rheumatoid arthritis, asthma, COPD, ALS, and the like.
The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof. Compounds of formula I are inhibitors of Janus kinases and as such are useful for the treatment of various diseases and conditions mediated by said enzymes, such as rheumatoid arthritis, asthma, COPD, ALS, and the like.
[EN] INHIBITING NEUROTRANSMITTER REUPTAKE<br/>[FR] INHIBITION DU RECAPTAGE DE NEUROTRANSMETTEURS
申请人:MAYO FOUNDATION
公开号:WO2014159251A3
公开(公告)日:2014-11-27
Structure−Activity Relationships of 9-Substituted-9-Dihydroerythromycin-Based Motilin Agonists: Optimizing for Potency and Safety
作者:Simon J. Shaw、Yue Chen、Hao Zheng、Hong Fu、Mark A. Burlingame、Saul Marquez、Yong Li、Mark Claypool、Christopher W. Carreras、William Crumb、Dwight J. Hardy、David C. Myles、Yaoquan Liu
DOI:10.1021/jm901107f
日期:2009.11.12
A series of 9-dihydro-9-acetamido-N-desmethyl-N-isopropyl erythromycin A analogues and related derivatives was generated as motilin agonists. The compounds were optimized for potency while showing both minimal antibacterial activity and hERG inhibition. As the substituent on the amide was increased in lipophilicity the potency and hERG inhibition increased, while polar groups lowered potency, without significantly impacting hERG inhibition. The N-methyl acetamide 7a showed the optimal in vitro profile and was probed further by varying the chain length to the macrocycle as well as changing the macrocycle scaffold. 7a remained the compound with the best in vitro properties.